Grand Pharmaceutical Group Limited (MX6A.F)
Frankfurt · EUR · Healthcare · Drug Manufacturers - Specialty & Generic
€0.47 (-1.67%) as of
Key statistics
- Market cap
- 1.70B
- P/E (TTM)
- 15.67
- EPS (TTM)
- 0.0300
- Dividend yield
- 3.87%
- 52-week range
- 0.4700 – 0.9550
- Beta
- 0.68
- Revenue (TTM)
- 12.48B
- Profit margin
- 8.89%
- Volume
- 100.00
About Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine, and health food products. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company has a strategic partnership with the University of Hong Kong for the research and development of drugs in the field of anti-infection and the industrialization of the research results. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited. The company was incorporated in 1995 and is based in Central, Hong Kong.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Central, Hong Kong
- Employees
- 12,326
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.